This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response

This study has been terminated.
(Study never accrued sufficient subjects)
Medical Research Foundation, Oregon
Radiological Society of North America
Information provided by (Responsible Party):
James Tanyi, OHSU Knight Cancer Institute Identifier:
First received: October 13, 2009
Last updated: March 24, 2016
Last verified: March 2016
The purpose of this study is to see if new techniques of measuring HNSCC tumors with magnetic resonance imaging (MRI) can help predict how well the tumors will respond to combined chemotherapy and radiation treatment. The investigators hope to find a reliable method to determine whether or not a patient's cancer is responding to chemo-radiation early in their treatment using an MRI, such that that cancer treatments could be tailored to the individual more effective in the future. The MRI techniques include dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted magnetic resonance imaging (DW-MRI), and magnetic resonance spectroscopy (MRS). Participants will be subjected to two sessions of MRI scans: one before the initiation of their regular treatment and the second before their second cycle of chemotherapy. Each scanning session will last approximately 45 minutes.

Condition Intervention
Head and Neck Cancer Other: DCE-MRI, DW-MRI and MRS

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study of DCE-MRI, DW-MRI, and MRS in the Assessment of Head and Neck Cancer Response to Chemo-radiation

Resource links provided by NLM:

Further study details as provided by James Tanyi, OHSU Knight Cancer Institute:

Primary Outcome Measures:
  • Determination of early or a prior prognostic markers of head and neck cancers, as measured by DCE-MRI, DW-MRI, and MRS, that characterize the differences between clinical responders and non-responders. [ Time Frame: September 2011 ]

Secondary Outcome Measures:
  • Correlation between early/a prior marker and progression-free survival. [ Time Frame: September 2011 ]

Enrollment: 10
Study Start Date: October 2011
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: DCE-MRI, DW-MRI and MRS

    Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.

    Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS.

Detailed Description:
DCE-MRI, DW-MRI, MRS have the potential to measure early cellular changes that occur in response to successful therapies, such as chemoradiation, and have been demonstrated to be early predictors not only of therapeutic response, but also of overall survival for other malignancies. Our long-term goal is to use these imaging techniques to develop non-invasive functional imaging methodologies that would be better predictors of pathological response than the current clinical standard.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Potential subjects will be recruited by the Oregon Health and Science University head and neck oncology staff.

Inclusion Criteria:

  • Histologically confirmed diagnosis of loco-regionally advanced (stage III or IV) squamous cell carcinoma of the head and neck (oropharynx, hypopharynx and larynx)
  • Age > 18 years
  • No prior surgery, chemotherapy or radiation therapy for head and neck cancer
  • Scheduled to receive chemoradiation for definitive therapy

Exclusion Criteria:

  • Contraindications to MRI (pacemaker, aneurysm clip, mechanical and/or electrical device or metallic fragment, severe claustrophobia)
  • Contraindications to gadolinium
  • Severe, active co-morbidity
  • Major medical illnesses or psychiatric impairments
  • Pregnant or nursing women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00994201

United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239-3098
Sponsors and Collaborators
OHSU Knight Cancer Institute
Medical Research Foundation, Oregon
Radiological Society of North America
Principal Investigator: James A. Tanyi, PhD Oregon Health and Science University
  More Information

Additional Information:
Responsible Party: James Tanyi, Clinical Associate Professor, OHSU Knight Cancer Institute Identifier: NCT00994201     History of Changes
Other Study ID Numbers: OHSU IRB00005554
Study First Received: October 13, 2009
Last Updated: March 24, 2016

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms processed this record on August 18, 2017